Amniotics AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMNI.ST research report →
Companywww.amniotics.com
Amniotics AB (publ) develops, manufactures, and sells stem cell therapies based on mesenchymal stem cells to treat severe life-threatening diseases. The company's lead drug candidate is PulmoStem for the treatment of inflammatory and fibrotic lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; and CutiStem for the treatment of dermatological indications.
- CEO
- Marcus Larsson
- IPO
- 2021
- Employees
- 4
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $14.76M
- P/E
- -0.49
- P/S
- 0.00
- P/B
- 0.98
- EV/EBITDA
- -0.34
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -362.71%
- ROIC
- -160.46%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-30,870,000 · 37.51%
- EPS
- $-0.01 · 96.33%
- Op Income
- $-29,073,000
- FCF YoY
- 35.47%
Performance & Tape
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.53
- Avg Volume
- 5.38M
Get TickerSpark's AI analysis on AMNI.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AMNI.ST Coverage
We haven't published any research on AMNI.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AMNI.ST Report →